Combined Holdings of Ionis Pharmaceuticals (IONS) - Updated Daily
TherapeuticsGenomicsRNA Therapy
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 0.71% | $5.04b |
| 🏋️♀️Weight Rank Across All Funds | 🌏Country |
| 28 | 🇺🇸United States |
| 💳ARK Estimated Cost Average | 🎫ARK Ownership Percent |
$43.70 - ARKG | 1.79% |
| Description | |
|---|---|
| For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Its scientific innovation began and continues with the knowledge that sick people depend on it, which fuels its vision of becoming one of the most successful biotechnology companies. | |
| Website | |
| www.ionispharma.com |